{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:24Z","timestamp":1789609224327,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Therapeutic Plasma Exchange (TPE) and Intravenous Immunoglobulin both are first\u2010line treatments for Guillain Barre Syndrome; however, there is a significant difference in cost. We undertook this study to assess the cost minimization for treating Guillain Barre Syndrome patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective randomized controlled trial was undertaken, in which 40 Guillain Barre Syndrome (GBS) patients with a GBS disability score of grade four and five were enrolled. A societal perspective was adopted for the analysis and assessment of both the health system cost and out\u2010of\u2010pocket expenditures. Cost\u2010minimization analysis was undertaken as both the treatments were equally effective at the end of 12\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No statistically significant differences were observed in the GBS Disability scores during overall treatment course in both treatment groups. The Out\u2010of\u2010pocket cost for the immunoglobulin (IVIG) group was INR 219\u2009247 (4298 USD) and for the TPE group was INR 104\u2009070 (2040.5 USD). Overall INR 86\u2009685 ($1700), that is, 53% higher cost was observed in IVIG group without any concomitant health outcome benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In comparison with IVIG, TPE appears to be the better option for treatment of GBS in cost\u2010constraint countries like ours to provide an economic treatment option to most average people.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jca.21646","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T13:34:30Z","timestamp":1539783270000},"page":"631-637","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cost\u2010minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-939X","authenticated-orcid":false,"given":"Ashish","family":"Maheshwari","sequence":"first","affiliation":[{"name":"Department of Transfusion Medicine PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratti R.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Prinja","sequence":"additional","affiliation":[{"name":"School of Public Health PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Hans","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Neurology PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Marwaha","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine PGIMER Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113378"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.100"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2011.09.002"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost\u2010Effectiveness in Health and Medicine","author":"Gold MR","year":"1996"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(99)00014-4"},{"key":"e_1_2_6_8_1","unstructured":"Cost minimization analysis. Introduction to Drug Utilization Research: Chapter 4: Economic Aspects of Drug Use (Pharmacoeconomy): 42 Cost\u2010Minimization Analysis.http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js4876e\/5.2.html. Accessed December 11 2017."},{"key":"e_1_2_6_9_1","unstructured":"Directorate OECDS. Gross Domestic Product. OECD Glossary of Statistical Terms \u2010 Gross domestic product (GDP) Definition.https:\/\/stats.oecd.org\/glossary\/detail.asp?ID=1163. Accessed December 11 2017."},{"key":"e_1_2_6_10_1","unstructured":"AmadeoK.What Real GDP per Capita Reveals About Your Lifestyle. The Balance.https:\/\/www.thebalance.com\/real-gdp-per-capita-how-to-calculate-data-since-1946-3306028. Accessed December 11 2017."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160986"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091781"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000184748"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1994.tb01665.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.6.893"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.5.605"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21433"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.1997.tb00027.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000050777"},{"issue":"1","key":"e_1_2_6_22_1","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2010Barre syndrome","volume":"25","author":"Hughes RA","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.635"},{"key":"e_1_2_6_24_1","first-page":"871","article-title":"Critically ill Guillain Barre syndrome","volume":"42","author":"Taly AB","year":"1994","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-101"},{"key":"e_1_2_6_27_1","unstructured":"Household Health Expenditures in India (2013\u201314). 2016 ed. New Delhi: National Health Systems Resource Centre. Ministry of Health and Family Welfare Government of India; December 2016.https:\/\/mohfw.gov.in\/sites\/default\/files\/38300411751489562625.pdf. Accessed December 11 2017."}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:09:43Z","timestamp":1720703383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/jca.21646"],"URL":"https:\/\/doi.org\/10.1002\/jca.21646","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"2017-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}